Recurrent Childhood Soft Tissue Sarcoma Completed Phase 2 Trials for Sirolimus (DB00877)

IndicationStatusPhase
DBCOND0029296 (Recurrent Childhood Soft Tissue Sarcoma)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01614795Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory SarcomaTreatment